Vernalis Plc (VER) - Financial and Strategic SWOT Analysis Review

Date: December 6, 2016
Pages: 65
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V0F77424931EN
Leaflet:

Download PDF Leaflet

Vernalis Plc (VER) - Financial and Strategic SWOT Analysis Review
Vernalis Plc (VER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Vernalis plc (Vernalis) is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a once-a-day formulation of the antibiotic (amoxicillin), indicated for the treatment of tonsillitis and pharyngitis secondary to Streptococcus pyogenes. It also specializes in fragment and structure based drug discovery. The company has collaboration agreements with leading pharmaceutical companies, including Novartis, Endo, GSK, Genentech, Biogen Idec, AKP, Menarini, Lundbeck, Servier, Taisho and Tris. Vernalis has operations in Europe and North America and is headquartered in Winnersh, the UK.

Vernalis Plc Key Recent Developments

Dec 01, 2016: Vernalis: AGM Statement
Sep 29, 2016: Vernalis Announces Results Announcement for the 12 Months Ended 30 June 2016
Jul 19, 2016: Vernalis achieves a milestone in its Oncology Collaboration with Servier
Apr 21, 2016: Vernalis Appoints Sandford Sommer as President & Chief Operating Officer, Vernalis Therapeutics
Mar 17, 2016: Vernalis: Unaudited Interim Results Announcement for the six months ended 31 December 2015

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

    Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

    Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

    Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

    Note: Some sections may be missing if data is unavailable for the company
  • SECTION 1 - ABOUT THE COMPANY

    Vernalis Plc - Key Facts
    Vernalis Plc - Key Employees
    Vernalis Plc - Key Employee Biographies
    Vernalis Plc - Major Products and Services
    Vernalis Plc - Pharmaceutical Pipeline Products Data
    Vernalis Plc, Pipeline Products by Therapy Area
    Vernalis Plc, Pipeline Products by Development Phase
    Vernalis Plc - History
    Vernalis Plc - Company Statement
    Vernalis Plc - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries

    SECTION 2 – COMPANY ANALYSIS

    Vernalis Plc - Business Description
    Vernalis Plc - Corporate Strategy
    Vernalis Plc - SWOT Analysis
    SWOT Analysis - Overview
    Vernalis Plc - Strengths
    Vernalis Plc - Weaknesses
    Vernalis Plc - Opportunities
    Vernalis Plc - Threats
    Vernalis Plc - Key Competitors

    SECTION 3 – COMPANY FINANCIAL RATIOS

    Financial Ratios - Capital Market Ratios
    Financial Ratios - Annual Ratios
    Performance Chart
    Financial Performance
    Financial Ratios - Interim Ratios
    Financial Ratios - Ratio Charts

    SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Vernalis Plc, Recent Deals Summary

    SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

    Dec 01, 2016: Vernalis: AGM Statement
    Sep 29, 2016: Vernalis Announces Results Announcement for the 12 Months Ended 30 June 2016
    Jul 19, 2016: Vernalis achieves a milestone in its Oncology Collaboration with Servier
    Apr 21, 2016: Vernalis Appoints Sandford Sommer as President & Chief Operating Officer, Vernalis Therapeutics
    Mar 17, 2016: Vernalis: Unaudited Interim Results Announcement for the six months ended 31 December 2015
    Mar 17, 2016: Vernalis Announces Unaudited Interim Results Announcement for the Six Months Ended 31 December 2015
    Sep 29, 2015: Vernalis: Results Announcement for the 18 months ended 30 June 2015
    Sep 29, 2015: Vernalis: Results announcement for 18 months ended 30/06/15
    Aug 18, 2015: Vernalis - Appointment of Non-Executive Director
    Jun 30, 2015: Vernalis Appointment of Non-Executive Director

    SECTION 6 – APPENDIX

    Methodology
    Ratio Definitions
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Vernalis Plc, Key Facts
    Vernalis Plc, Key Employees
    Vernalis Plc, Key Employee Biographies
    Vernalis Plc, Major Products and Services
    Vernalis Plc, Number of Pipeline Products by Therapy Area
    Vernalis Plc, Number of Pipeline Products by Development Stage
    Vernalis Plc, Pipeline Products By Therapy Area and Development Phase
    Vernalis Plc, History
    Vernalis Plc, Subsidiaries
    Vernalis Plc, Key Competitors
    Vernalis Plc, Ratios based on current share price
    Vernalis Plc, Annual Ratios
    Vernalis Plc (Cont...1), Annual Ratios
    Vernalis Plc, Interim Ratios
    Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Vernalis Plc, Recent Deals Summary
    Currency Codes
    Capital Market Ratios
    Equity Ratios
    Profitability Ratios
    Cost Ratios
    Liquidity Ratios
    Leverage Ratios
    Efficiency Ratios

    LIST OF FIGURES

    Vernalis Plc, Pipeline Products by Therapy Area
    Vernalis Plc, Pipeline Products by Development Phase
    Vernalis Plc, Performance Chart (2012 - 2016)
    Vernalis Plc, Ratio Charts
    Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Vernalis Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
    Skip to top


    Ask Your Question

    Vernalis Plc (VER) - Financial and Strategic SWOT Analysis Review
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: